Replies to post #109598 on Biotech Values

[DewDiligence]

GILD receives FDA Refusal-to-File letter for ‘Btripla’:

http://finance.yahoo.com/news/Gilead-Sciences-Receives-bw-2933689778.html?x=0&.v=1

Btripla is the combination pill consisting of GILD’s Truvada and JNJ’s TMC278. TMC278 is a qD NNRTI from JNJ that is similar to Intelence with better pharmacokinetics (#msg-57177651).

The RTF letter is clearly a surprising development.